LONDON (Alliance News) - GlaxoSmithKline PLC on Tuesday said it received positive results from studies carried out on its Advair Diskus asthma treatment and on its Shingrix treatment for shingles.
The FTSE 100-listed drugmaker said its LABA safety study on Advair Diskus showed a safety level equivalent to fluticasone propionate monotherapy in treating adolescent and adult patients with asthma. Advair Diskus uses a combination of fluticasone propionate and salmeterol.
In addition, Glaxo said a study carried out on Shingrix showed the treatment hit its primary endpoint of achieving 90% efficacy in treating patients aged over 70 with shingles.
The company intends to file a regulatory application for Shingrix for preventing shingles in people aged 50 and over in North America, Japan and the European Union in the second half of 2016.
Glaxo shares were down 0.3% to 1,364.93 pence on Tuesday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.